Arthex Biotech
Focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs.
- biotechnology
- horizon europe
- dt and ls
- woman founder
- spinout
- biotech and pharma
- eit ecosystem
- genetics and genomics
- drug development
- eit health
- genome engineering
- ai drug discovery
- eit supernovas
- research and development
- techbio
- eicfund
- digital pharma
- techbio drug discovery
- headstart (eit health)
- rna
- headstart 2020 (eit health)
- caixa impulse (eit health)
- caixa impulse 2017 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €42.0m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 686 % | 50 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (1444 %) | (590 %) | (1159 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (1444 %) | (616 %) | (1561 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Developer of anti-microRNAs designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders in which microRNAs play a role, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs.
Keywords: Pharmaceuticals and Biotechnology, Antisense Oligonucleotide, Antisense Oligonucleotide Therapy, Muscular Dystrophy, Neuromuscular Disease, Neuromuscular Disease Therapeutics, Neuromuscular Disease Treatment, Neuromuscular Therapy, Oligonucleotide Therapeutics, Oligonucleotide Therapy.